"Allen brings a unique wealth of data, analytics and commercialization experience in the healthcare industry, and has achieved tremendous success in his career as both an executive and entrepreneur," said Ido Hadari, Treato's Chief Executive Officer. "We are very pleased to welcome him to the team as we continue to expand our reach across the industry".
Allen Kamer brings nearly 25 years of health care experience, primarily focused on commercializing innovative health care solutions. He co-founded Humedica, a transformative population health and analytics company which was sold to UnitedHealth (NYSE: UNH) in 2013. Following the acquisition, Allen served as the Chief Commercial Officer of Optum Analytics (a division in Optum, UnitedHealth Group's health services company). As the CCO, he led the group's commercialization efforts of analytics software products and solutions, including the award-winning Optum One™, to U.S. provider and payer organizations. Allen previously also held management positions at leading healthcare investment bank, Leerink Swann (now Leerink Partners), and at Biogen. He began his career reporting on FDA and policy issues for The Pink Sheet, and received his BA from Brandeis University.
"A new area of healthcare is emerging - consumer and patient-driven health care. In many instances, individual patients are becoming the focal point that drives the healthcare industry, not the other way around," said Allen Kamer. "Treato has applied its patented technology to social data and categorized incredible insights from patients. I am excited to join the Treato Board as the company prepares to expand its footprint and penetrate new areas," he added.
"We are excited to have Allen work with us towards putting patients front and center", said Anat Naschitz, Managing Director at OrbiMed Advisors.
Treato™, the leading source of healthcare insights from millions of real consumers, uses patented analytics and big data technology to turn billions of disparate online personal experiences into meaningful social intelligence. With more than three billion conversations analyzed and continuously expanding, Treato provides the patient-centric perspective in a consumer-driven healthcare environment. Treato has partnered with dozens of pharmaceutical companies and healthcare organizations, and treato.com, its consumer website helps millions of visitors each month.
Treato is privately held with offices in Israel and Princeton, NJ. Investors include Reed Elsevier Ventures, OrbiMed Partners and New Leaf Venture Partners, among others. For more information please visit https://treato.com/